Press Release, Lund November 26, 2020
Today we release the film “This is Hamlet” made by the two TV journalists Calle Magnell and Fredrik Kron in collaboration with Jan-Olof Bengtsson.
The movie tells the exiting story about the discovery of HAMLET and its potential as a new cancer treatment. You will meet the multinational and talented research team members, who will tell you about their favorite topics within the HAMLET project. You will also meet the principal investigator from the University Hospital in Prague, who is carrying out the important clinical studies in patients with bladder cancer together with his team.
The film illustrates how a discovery can be translated to clinical reality, with the support of a Biotech company structure and our shareholders, as well as public funding and support from the European Union. We hope that you will find the film informative and inspiring.
This first version is produced in Swedish and an English version will be released soon.
Please see below or click on https://youtu.be/JHv7Ct787xI
For more information, please contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46-705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.
The project is coordinated by Prof. Catharina Svanborg and CEO Mats Persson of Hamlet Pharma. This project is funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 954360.